TX-EAGLE-EYE-NETWORKS
30.9.2021 13:02:11 CEST | Business Wire | Press release
Eagle Eye Networks, the global leader in cloud video surveillance, today announced the acquisition of artificial intelligence leader Uncanny Vision, accelerating the company’s leadership in providing AI and analytics to make customers’ businesses more efficient and the world a safer place. The acquisition also includes research and development capabilities and a new regional office in Bangalore, India.
“After evaluating more than a dozen AI companies, we began working with Uncanny Vision in 2020. It didn’t take long for us to conclude that Uncanny Vision is the clear leader in surveillance AI,” said Dean Drako, Eagle Eye Networks CEO. “Their award-winning AI technology is deployed across thousands of locations, including Fortune 500 customers.”
The deal accelerates Eagle Eye’s plan, announced in November 2020 , when Eagle Eye raised funds from venture capital firm Accel, to dramatically reshape video surveillance.
Uncanny Vision’s deep learning algorithms enable recognition, identification, and prediction, improving business operations, customer service, and site safety. Uncanny Vision’s award-winning AI is used today in multiple applications, including:
- Smart parking
- Retail analytics
- Gate security
- Toll automation
- Smart cities
- ATM monitoring
- Worker safety
- Perimeter security
Drako said, “Uncanny Vision’s tools for training, building, and optimizing models, and its infrastructure for managing and storing training data are superior. This is a key component we’re excited to add to the Eagle Eye Networks platform.”
All 60 Uncanny Vision employees will be retained, and Eagle Eye plans to expand the Bangalore office. Eagle Eye is committed to supporting Uncanny Vision’s current customers, and will continue to build its global infrastructure to provide the very best 24/7 support to its valued customers around the world.
Uncanny Vision co-founders, Ranjith Parakkal and Navaneethan Sundaramoorthy, have joined the Eagle Eye leadership team. Parakkal said, “We share the Eagle Eye team’s vision to deliver advanced, cyber secure AI cloud video surveillance offerings that transform video surveillance for businesses around the globe.”
"The economic model of delivering subscription-based AI on a per-camera basis through a global cloud infrastructure will ignite growth for security integrators who are otherwise challenged with how to build a financially stable business," said Alper Cetingok, Managing Director and Head of the Security & Safety Practice at Raymond James.[1]
ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is No. 1 in cloud video surveillance worldwide. Our 100% cloud managed solutions provide cloud and on-premises recording, bank-level security and encryption, and broad analog and digital camera support – all accessed via the web or mobile applications. Eagle Eye Networks delivers cyber secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. All products benefit from Eagle Eye’s developer friendly RESTful API platform and Big Data Video FrameworkTM . Headquartered in Austin, Texas, Eagle Eye has offices in Bangalore, Tokyo, and Amsterdam. For more information, visit www.een.com .
ABOUT UNCANNY VISION
Founded in 2013, Uncanny Vision is an award-winning AI-based computer vision company delivering next generation intelligent surveillance solutions for smart cities, smart buildings and infrastructure specifically for people and vehicle monitoring using cameras. Uncanny Vision surveillance enables cameras to "see" and "understand" their environment instantly, using optimized real-time AI/deep learning algorithms. For more information, visit www.uncannyvision.com .
[1] Raymond James & Associates was not a party to the transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005143/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom